Back to Agenda
Joint Session 1 – Part II: CTR Transparency – Business Considerations
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure
AbbVie, United States
Rose-Marie Swallow
Senior Manager, Policy & Research
Bayer Plc., United Kingdom
The second part of this opening session will concentrate on the transparency aspects of the Clinical Trial Regulation and what this will mean in practice for Sponsors of clinical trials in the future. Following on from the demonstration of the public view of CTIS given in Part 1, this session will examine what this will mean to Sponsors in practice. The session will try to clarify what documentation will be published and when, what data protection considerations Sponsors need to be aware of and what opportunities will be available for Sponsors to use to protect their intellectual property in the future. The panel discussion at the end will afford an opportunity for attendees to raise questions and for further discussion of this topic with representatives of the main stakeholders including, the Commission, EMA, Member States and Sponsors.
Speaker(s)
Sponsor Preparedness – Points to Consider
Ruediger Pankow, DrSc
Germany
Regulatory Affairs Expert, CTIS SME and PO
Panel Discussion, with the participation of:
Elke Stahl, PhD
Federal Institute For Drugs and Medical Devices (BfArM), Germany
Senior Expert, Clinical Trials Department
Contributing Panelist
Pierre-Frederic Omnes, MPharm
TransPerfect, France
Executive Director, Life Sciences
Contributing Panelist
Laura Pioppo, MSc
European Medicines Agency, Netherlands
Scientific Administrator, CTIS expert
Contributing Panelist
Nick Sykes, MS
EFPIA, Belgium
Policy Advisor
Contributing Panelist
Ruediger Pankow, DrSc
Germany
Regulatory Affairs Expert, CTIS SME and PO
Contributing Panelist
Kristof Bonnarens, MPharm
European Commission, Belgium
Policy Officer Pharmaceuticals
Have an account?